• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis

Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis

Details
Publisher DOI
10.1160/TH07-07-0444
PubMed ID
18064314
Abstract
No data about the use of the pentasaccharide fondaparinux, a highly selective indirect inhibitor of factor Xa, in patients treated with haemodialysis are available. Therefore, we investigated the pharmacokinetics and -dynamics of fondaparinux in 12 patients during haemodialysis. The anti-Xa activity (expressed as fondaparinux equivalent) was monitored, a semiquantitative clotting scale (SQCS) ranging from 0 (no visible traces of coagula) to 3 (complete clotting of the dialysis circuit) was applied, and the digital compression time necessary to achieve haemostasis at the puncture site was determined. After an initial period, when the regular heparin dose was replaced once weekly by fondaparinux, 0.05 mg/kg, the pentasaccharide was administered for nine consecutive haemodialysis sessions. Peak anti-Xa activity increased from 0.61 +/- 0.14 microg/l after the first dose to 0.89 +/- 0.24 microg/l after dose 9 (P < 0.001), whereas predialysis anti-Xa activity steadily rose to 0.32 +/- 0.09 microg/l (P < 0.001). A sufficient but slightly less effective anticoagulation with a mean SQCS of 1.19 +/- 0.71 (n = 121) was obtained by fondaparinux as compared with 0.65 +/- 0.58 (n = 60, P < 0.005) by 4,825 +/- 1,703 U of unfractionated heparin. Mean digital compression time rose slightly during fondaparinux from 23.7 +/- 7.4 minutes to 24.8 +/- 7.5 minutes (P < 0.05) and, more important, six of the 12 patients reported minor bleeding problems during the interdialytic interval. Thus, fondaparinux can be used to prevent circuit clotting during haemodialysis; however, accumulation results in an interdialytic increase of anti-Xa activity. Therefore, fondaparinux should be reserved for patients requiring systemic anticoagulation on the days off dialysis.
Date Issued
2007
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Author(s)
Kalicki, Robert  
Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie  
Aregger, Fabienne  
Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie  
Alberio, Lorenzo  
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Lämmle, Bernhard  
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Frey, Felix  
Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie  
Uehlinger, Dominik  
Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie  
Additional Credits
Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie  
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Journal
Thrombosis and haemostasis
Publisher
Schattauer
ISSN
0340-6245
ISBN
18064314
Access(Rights)
metadata.only
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify